Abstract:The therapeutic approach of targeted protein degradation (TPD) is gaining momentum due to its potentially superior effects compared with protein inhibition. Recent advancements in the biotech and pharmaceutical sectors have led to the development of compounds that are currently in human trials, with some showing promising clinical results. However, the use of computational tools in TPD is still limited, as it has distinct characteristics compared with traditional computational drug design methods. TPD involves creating a ternary structure (protein-degrader-ligase) responsible for the biological function, such as ubiquitination and subsequent proteasomal degradation, which depends on the spatial orientation of the protein of interest (POI) relative to E2-loaded ubiquitin. Modeling this structure necessitates a unique blend of tools initially developed for small molecules (e.g., docking) and biologics (e.g., protein-protein interaction modeling). Additionally, degrader molecules, particularly heterobifunctional degraders, are generally larger than conventional small molecule drugs, leading to challenges in determining drug-like properties like solubility and permeability. Furthermore, the catalytic nature of TPD makes occupancy-based modeling insufficient. TPD consists of multiple interconnected yet distinct steps, such as POI binding, E3 ligase binding, ternary structure interactions, ubiquitination, and degradation, along with traditional small molecule properties. A comprehensive set of tools is needed to address the dynamic nature of the induced proximity ternary complex and its implications for ubiquitination. In this Perspective, we discuss the current state of computational tools for TPD. We start by describing the series of steps involved in the degradation process and the experimental methods used to characterize them. Then, we delve into a detailed analysis of the computational tools employed in TPD. We also present an integrative approach that has proven successful for degrader design and its impact on project decisions. Finally, we examine the future prospects of computational methods in TPD and the areas with the greatest potential for impact.

Targeted Protein Degradation Systems: Controlling Protein Stability Using E3 Ubiquitin Ligases in Eukaryotic Species

Targeted Protein Degradation: Principles, Strategies, and Applications

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeted protein degradation: from mechanisms to clinic

Targeted protein degradation as a powerful research tool in basic biology and drug target discovery

Control of protein stability by post-translational modifications

Targeted protein degradation in mammalian cells: A promising avenue toward future

Proteome-scale discovery of protein degradation and stabilization effectors

Narrative Review: Protein Degradation and Human Diseases: The Ubiquitin Connection

Novel approaches to targeted protein degradation technologies in drug discovery

Recent advances in targeted protein degraders as potential therapeutic agents

Bivalent Ligands for Protein Degradation in Drug Discovery

Emerging Targeted Protein Degradation Tools for Innovative Drug Discovery: from Classical PROTACs to the Novel and Beyond.

Targeted protein degradation: expanding the toolbox

Key Considerations in Targeted Protein Degradation Drug Discovery and Development

Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods

Advancing targeted protein degradation for cancer therapy

Targeted protein degradation in drug development: Recent advances and future challenges

Protein degradation technology: a strategic paradigm shift in drug discovery.

From the Evasion of Degradation to Ubiquitin-Dependent Protein Stabilization

Current Challenges in Small Molecule Proximity-Inducing Compound Development for Targeted Protein Degradation Using the Ubiquitin Proteasomal System